Tickerover
Healthcare

COLL Stock Analysis

Collegium Pharmaceutical, Inc. · current price $25.31 (-3.98% today)

Mixed signals — neither side has the edge here. The thesis lacks a clear edge from current data.
★★★
Average
📊

The six-pillar scorecard

Momentum
0
In a downtrend
price trend
Growth
25
Barely growing
sales & profit growth
Quality
78
High quality
profitability & balance sheet
Valuation
75
Looks cheap
is the price fair?
Sentiment
42
Mixed views
analyst & crowd mood
Risk
50
Above-avg risk
volatility & drawdown

Each pillar is scored 0-100 inside the stock’s own peer group, so a chipmaker is measured against chipmakers. These are quality descriptors, not buy or sell signals.

📉

The picture

What drove the scoreThe seven components contributing most, each read out of 100.
GrowthGrowth: 5555Near 52w highNear 52w high: 100100FundamentalsFundamentals: 9292Earnings qualityEarnings quality: 8484Earnings accelerationEarnings acceleration: 8888News sentimentNews sentiment: 8282VolumeVolume: 5050
Margin profileWhat survives each step down the income statement.
GrossGross: 89.4%89.4%OperatingOperating: 5.7%5.7%NetNet: 5.9%5.9%Free cash flowFree cash flow: 40.6%40.6%
EPS surpriseReported EPS against estimate, last four quarters.
2026-06: +8.8% vs estimate+9%2026-062026-03: +15.5% vs estimate+16%2026-032025-12: -4.7% vs estimate-5%2025-122025-09: +21.0% vs estimate+21%2025-09
👁

Hype Check

Reading COLL’s price and volume history…

The audit — what has to hold for this thesis

Checking the areas that decide this thesis…

AI-generated from the company’s own filings and recent coverage, and it can be incomplete or wrong. A PASS is a reading of the cited evidence, not a verified fact and not a reason to buy. Follow each citation to the source.

🛡

Dilution Check

Reading COLL’s filings…

📣

Latest earnings

LAST EARNINGS Collegium Pharmaceutical, Inc. (COLL)

Latest earnings

EPS
$2.25 vs $1.86 est · +21.0% vs estimate BEAT
Revenue
$199.9M · -4.5% YoY
Stock reaction (1M)
-29.5%
Beat streak
3 of last 4 quarters
💰

Valuation

P/E
20.0×
Forward P/E
3.7×
Price / Sales
1.0×
Price / Book
2.6×
EV / EBITDA
4.7×
Analyst target
$49.60
Target range
$43.00 – $60.00
Implied upside
+96.0%
🩺

Financial health

Gross margin
89.4%
Operating margin
5.7%
Net margin
5.9%
FCF margin
40.6%
Return on equity
17.6%
Debt / equity
3.90
Revenue growth YoY
+6.3%
📈

Technicals

$25.1652-week range$50.79
RSI (14)
28
50-day MA
$32.89
200-day MA
$38.60
ATR (14)
1.33
Beta
0.76
1-month return
-29.5%
🗓️

Earnings

QuarterEPSEst.SurpriseResult
2025-09-30$2.25$1.86+21.0%Beat
2025-12-31$2.04$2.14-4.7%Miss
2026-03-31$1.76$1.52+15.5%Beat
2026-06-30$1.92$1.76+8.8%Beat
Beat 3 of the last 4 quarters.
🏛️

Ownership & risk

Short % of float
0.24%
Beta
0.76
📰

Latest news on COLL

🔗

Similar stocks in Healthcare

Frequently asked

What is COLL's Quant Score?

Collegium Pharmaceutical, Inc. (COLL) currently has a TickerMover Quant Score of 51/100, rated ★★★ Average. The Quant Score is a quantitative composite across six research pillars — momentum, quality, growth, valuation, sentiment and risk. It is research information, not investment advice.

Is Collegium Pharmaceutical, Inc. (COLL) a buy?

TickerMover does not give buy or sell recommendations. COLL scores 51/100 (★★★ Average) on our quantitative research model — a screening signal, not a personal recommendation. Do your own research, and consider an FCA-authorised adviser before investing.

How often is COLL's score updated?

COLL's Quant Score and underlying data refresh through US market hours (about every five minutes), using public market and fundamental data.

Get the full live dashboard

Real-time scoring, conflict detection, Reverse DCF and peer comparison — free while in beta.

Open the dashboard for COLL →